2024-512771-12-00CompletedPhase 1
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 21 Mar 2024
- Start date
- 17 Sept 2024
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- EU CT number
- 2024-512771-12-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 32
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Terapia S.A. | Cluj-Napoca | Romania | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.